Barinthus Biotherapeutics (BRNS) Total Liabilities (2020 - 2026)

Barinthus Biotherapeutics has reported Total Liabilities for 7 years, with the latest figure at $25.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 2.8% year-over-year to $25.7 million; the trailing twelve-month figure through Mar 2026 stood at $25.7 million (down 2.8% YoY), and the FY2025 full-year result was $23.9 million, down 20.92% from the prior year.
• Total Liabilities for Q1 2026 stood at $25.7 million, up from $23.9 million in the prior quarter.
• The five-year high for Total Liabilities was $34.4 million in Q3 2023, with the low at $23.9 million in Q4 2025.
• Historically, Total Liabilities has averaged $28.5 million across 5 years, with a median of $28.2 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 227.08% — and 2025, when it decreased 20.92%.
• Barinthus Biotherapeutics' Total Liabilities stood at $27.0 million in 2022, then increased by 1.88% to $27.5 million in 2023, then gained by 9.75% to $30.2 million in 2024, then declined by 20.92% to $23.9 million in 2025, then rose by 7.49% to $25.7 million in 2026.
• The last three Total Liabilities figures came in at $25.7 million (Q1 2026), $23.9 million (Q4 2025), and $24.6 million (Q3 2025), per Business Quant data.